Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
pharmacology, toxicology and pharmaceutics
Nigella sativa Supplementation Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial
Phytotherapy Research, Volume 31, No. 3, Year 2017
Notification
URL copied to clipboard!
Description
Poor compliance with conventional asthma medications remains a major problem in achieving asthma control. Nigella sativa oil (NSO) is used traditionally for many inflammatory conditions such as asthma. We aimed to investigate the benefits of NSO supplementation on clinical and inflammatory parameters of asthma. NSO capsules 500 mg twice daily for 4 weeks were used as a supplementary treatment in a randomized, double-blind, placebo-controlled trial in asthmatics (clinicaltrials.gov: NCT02407262). The primary outcome was Asthma Control Test score. The secondary outcomes were pulmonary function test, blood eosinophils and total serum Immunoglobulin E. Between 1 June and 30 December 2015, 80 asthmatics were enrolled, with 40 patients in each treatment and placebo groups. After 4 weeks, ten patients had withdrawn from each group. Compared with placebo, NSO group showed a significant improvement in mean Asthma Control Test score 21.1 (standard deviation = 2.6) versus 19.6 (standard deviation = 3.7) (p = 0.044) and a significant reduction in blood eosinophils by −50 (−155 to −1) versus 15 (−60 to 87) cells/μL (p = 0.013). NSO improved forced expiratory volume in 1 second as percentage of predicted value by 4 (−1.25 to 8.75) versus 1 (−2 to 5) but non-significant (p = 0.170). This randomized, double-blind, placebo-controlled trial demonstrated that NSO supplementation improves asthma control with a trend in pulmonary function improvement. This was associated with a remarkable normalization of blood eosinophlia. Future studies should follow asthmatics for longer periods in a multicentre trial. Copyright © 2017 John Wiley & Sons, Ltd.
Authors & Co-Authors
Koshak, Abdulrahman E.
United Kingdom, London
Ucl School of Pharmacy
Saudi Arabia, Jeddah
King Abdulaziz University
Wei, Li
United Kingdom, London
Ucl School of Pharmacy
Koshak, Emad Abdulkader
Saudi Arabia, Jeddah
King Abdulaziz University
Wali, Siraj Omar
Saudi Arabia, Jeddah
King Abdulaziz University
Alamoudi, Omer S.B.
Saudi Arabia, Jeddah
King Abdulaziz University
Demerdash, Abdulrahman
Saudi Arabia, Jeddah
King Abdulaziz University
Qutub, Majdy Mohammed Ali
Saudi Arabia, Jeddah
King Abdulaziz University
Pushparaj, Peter Natesan
Saudi Arabia, Jeddah
King Abdulaziz University
Heinrich, Michael M.
United Kingdom, London
Ucl School of Pharmacy
Statistics
Citations: 71
Authors: 9
Affiliations: 2
Identifiers
Doi:
10.1002/ptr.5761
ISSN:
0951418X
e-ISSN:
10991573
Research Areas
Disability